Publications: Dr Patrick Kennedy

Gish RG, Wong RJ, Di Tanna GL, Kaushik A, Kim C, Smith NJ, Kennedy PTF ( 2024 ) . Reply: The causal analysis of missing confounding factors for the association between HDV and specific liver events . Hepatology vol. 80 , ( 4 ) e50 - e52 .

Cross A, Harris JM, Arbe-Barnes E, Nixon C, Dhairyawan R, Hall A, Quaglia A, Issa F et al. ( 2024 ) . Characterisation of HBV and co-infection with HDV and HIV through spatial transcriptomics . eGastroenterology vol. 2 , ( 3 )

Zoulim F, Chen P-J, Dandri M, Kennedy PT, Seeger C ( 2024 ) . Hepatitis B Virus DNA integration: Implications for diagnostics, therapy, and outcome . Journal of Hepatology

Sun B, da Costa KAS, Alrubayyi A, Kokici J, Fisher-Pearson N, Hussain N, D’Anna S, Piermatteo L et al. ( 2024 ) . HIV/HBV coinfection remodels the immune landscape and natural killer cell ADCC functional responses . Hepatology vol. 80 , ( 3 ) 649 - 663 .

Abbott J, Aldhouse NVJ, Kitchen H, Pegram HC, Brown F, Macartney M, Villasis-Keever A, Sbarigia U et al. ( 2024 ) . A conceptual model for chronic hepatitis B and content validity of the Hepatitis B Quality of Life (HBQOL) instrument . Journal of Patient-Reported Outcomes vol. 8 , ( 1 )

Zeng G, Holmes BR, Alqahtani SA, Gill US, Kennedy PTF ( 2024 ) . The co-existence of NAFLD and CHB is associated with suboptimal viral and biochemical response to CHB antiviral therapy: a systematic review and meta-analysis . Frontiers in Gastroenterology vol. 3 ,

Salpini R, Svicher V, Kennedy PT ( 2024 ) . Editorial: The current challenges underlying hepatitis D virus infection . Frontiers in Medicine vol. 10 ,

Moy JN, Amin AM, Chalmers-Watson C, Chowdhury R, Forssten C, Fu J, Ghosh S, Harris JD et al. ( 2023 ) . Evaluation of the Panbio™ COVID-19 IgG rapid test device performance . Heliyon vol. 9 , ( 12 )

Mak L, Koffas A, Dolman GE, Saleh H, Kemos P, Riddell A, Gill U, Kennedy PTF ( 2023 ) . Role of HBsAg levels in guiding hepatitis B virus prophylaxis in pregnancy: Insights from a multi‐ethnic cohort . Journal of Viral Hepatitis vol. 31 , ( 1 ) 3 - 11 .

Gish RG, Wong RJ, Di Tanna GL, Kaushik A, Kim C, Smith NJ, Kennedy PTF ( 2023 ) . Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis . Hepatology vol. 79 , ( 5 ) 1129 - 1140 .

Testoni B, Suarez AAR, Battisti A, Plissonnier M-L, Heil M, Fontanges T, Villeret F, Chouik Y et al. ( 2023 ) . Evaluation of the HBV liver reservoir with fine needle aspirates . JHEP Reports vol. 5 , ( 10 )

Yuen M-F, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, Hou JL, Kakuda TN et al. ( 2023 ) . Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial . The Lancet Gastroenterology & Hepatology vol. 8 , ( 9 ) 790 - 802 .

Lim Y-S, Kim WR, Dieterich D, Kao J-H, Flaherty JF, Yee LJ, Roberts LR, Razavi H et al. ( 2023 ) . Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B . Viruses vol. 15 , ( 4 )

Zeng G, Koffas A, Mak L-Y, Gill US, Kennedy PTF ( 2023 ) . Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies . JHEP Reports vol. 5 , ( 6 )

Pallett LJ, Swadling L, Diniz M, Maini AA, Schwabenland M, Gasull AD, Davies J, Kucykowicz S et al. ( 2023 ) . Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS . Nature vol. 614 , ( 7947 ) 334 - 342 .

Koffas A, Mak L, Kennedy PTF ( 2023 ) . Hepatitis delta virus: Disease assessment and stratification . Journal of Viral Hepatitis vol. 30 , ( S1 ) 12 - 21 .

Testoni B, Suarez AAR, Battisti A, Plissonnier M-L, Heil M, Fontanges T, Villeret F, Chouik Y et al. ( 2023 ) . Evaluation of the hepatitis B virus liver reservoir with fine needle aspirates . JOURNAL OF HEPATOLOGY . vol. 78 , S118 - S119 .

Lampertico P, Asselah T, Gane EJ, Fung SK, Kennedy P, Vanwolleghem T, Janczewska E, zur Wiesch JS et al. ( 2023 ) . Intrahepatic characterization of virological and immunological markers in two distinct populations of chronic hepatitis B: baseline assessment of core liver and fine needle aspiration biopsies from the investigational INSIGHT study . JOURNAL OF HEPATOLOGY . vol. 78 , S1034 - S1035 .

Mak LYL, Koffas A, Wellington S, Stretch S, Riddell A, Yuen M-F, Kennedy P, Gill U ( 2023 ) . Nucleotide analogue therapy does not reverse the hyperexpression of innate-like markers on activated T cells consistent with immunopathology in chronic hepatitis B . JOURNAL OF HEPATOLOGY . vol. 78 , S1033 - S1033 .

Swinnen K, Jeng W-J, Romero-Gomez M, Zeuzem S, Kennedy PS, Zoulim F, Vanwolleghem T, Haque N et al. ( 2023 ) . POTENT AND POLYFUNCTIONAL HEPATITIS B CORE (HBC)/SURFACE (HBS)-SPECIFIC CD8+AND CD4+T CELL RESPONSES OBSERVED IN ADULTS WITH CHRONIC HEPATITIS B (CHB) FOLLOWING TARGETED IMMUNOTHERAPY CONSISTING OF VIRAL VECTORS IN HETEROLOGOUS PRIME-BOOST REGIMEN AND ADJUVANTED HBC/HBS PROTEINS: RESULTS ON STEP B COHORT OF A PHASE I/II TRIAL . HEPATOLOGY . vol. 77 , E146 - E146 .

Le Bert N, Koffas A, Tan A, Mak L-Y, Stretch S, Hang SK, Ma H, Lee A et al. ( 2023 ) . Rapid functional secretome analysis of HBV-specific T cells to guide clinical management of CHB patients . JOURNAL OF HEPATOLOGY . vol. 78 , S1024 - S1025 .

Gish RG, Toumi M, Wallace J, Cohen C, Wang S, Marshall C, Kitchen H, Macey J et al. ( 2023 ) . Self-stigma in chronic hepatitis B: content and psychometric validation of a new patient-reported outcome instrument . JOURNAL OF HEPATOLOGY . vol. 78 , S1087 - S1088 .

Abbott J, Kennedy P, Dhairyawan R ( 2023 ) . Treatment experience and acceptability in a UK HBV cohort- why personalised regimens may be necessary in chronic hepatitis B . JOURNAL OF HEPATOLOGY . vol. 78 , S1127 - S1127 .

Salpini R, Piermatteo L, D'Anna S, Duca L, Torre G, Guerra AF, Boarini C, Tavelli A et al. ( 2023 ) . Ultrasensitive HBV-RNA quantification by droplet digital PCR is a promising biomarker to optimize the staging of chronic HBV infection and to identify minimal viral activity under prolonged virological suppression . JOURNAL OF HEPATOLOGY . vol. 78 , S1105 - S1105 .

Khalfi P, Kennedy PT, Majzoub K, Asselah T ( 2022 ) . Hepatitis D virus: Improving virological knowledge to develop new treatments . Antiviral Research vol. 209 ,

Hansi N, Mak LL-Y, Gill U, Kennedy P ( 2022 ) . Chronic Hepatitis B . Liver Disease in Clinical Practice , Springer Nature

Mak L-Y, Beasley I, Kennedy PTF ( 2022 ) . Chronic Viral Hepatitis in Elite Athletes: Approaches to Risk Assessment, Prevention and Management . Sports Medicine - Open vol. 8 , ( 1 )

Mak L-Y, Beasley I, Kennedy PTF ( 2022 ) . Chronic viral hepatitis in athletes: an overlooked population? . British Journal of Sports Medicine vol. 57 , ( 2 ) 72 - 74 .

Abbott J, Elangovan ML, Kennedy P ( 2022 ) . OP36 The virtual patient group: an effective way of engaging patients and gathering essential feedback to improve service delivery and medical care for Chronic Hepatitis B patients . Conference: Abstractsa29.3 - a2a30 .

Loey Mak LY, Koffas A, Dolman G, Saleh H, Kemos P, Riddell A, Gill U, Kennedy P ( 2022 ) . P75 Inter-ethnic differences of quantitative hepatitis B surface antigen (qHBsAg) in predicting highly viraemic pregnancy with chronic hepatitis B infection . Conference: Abstractsa87 - a89 .

Salpini R, D'Anna S, Benedetti L, Piermatteo L, Gill U, Svicher V, Kennedy PTF ( 2022 ) . Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure . Frontiers in Microbiology vol. 13 , 972687 - 972687 .

Koffas A, Mak L-Y, Gill US, Kennedy PTF ( 2022 ) . Early Treatment Consideration in Patients with Hepatitis B ‘e’ Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift? . Viruses vol. 14 , ( 5 )

Usai C, Gill US, Riddell AC, Asselah T, Kennedy PT ( 2022 ) . Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus . Alimentary Pharmacology & Therapeutics vol. 55 , ( 8 ) 978 - 993 .

Khoo NKH, Lim JME, Gill US, de Alwis R, Tan N, Toh JZN, Abbott JE, Usai C et al. ( 2022 ) . Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients . Med vol. 3 , ( 2 ) 104 - 118.e4 .

Usai C, Gibbons JM, Pade C, Li W, Jacobs SRM, McKnight Á, Kennedy PTF, Gill US ( 2022 ) . The β-NGF/TrkA Signalling Pathway Is Associated With the Production of Anti-Nucleoprotein IgG in Convalescent COVID-19 . Frontiers in Immunology vol. 12 ,

Pallett LJ, Diniz M, Swadling L, Skelton J, Maini A, Davies J, Kucykowicz S, Schmidt N et al. ( 2022 ) . CD8+T cell acquisition of the LPS receptor within the hepatic stroma shapes anti-viral/anti-tumour potential . JOURNAL OF HEPATOLOGY . vol. 77 , S55 - S56 .

Salpini R, Carioti L, Battisti A, Piermatteo L, Benedetti L, Silberstein FC, Gill U, Svicher V et al. ( 2022 ) . Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the setting of HBeAg positive infection . JOURNAL OF HEPATOLOGY . vol. 77 , S284 - S284 .

Phillips S, Mistry S, Harris N, Moore C, Hahn G, Rosario M, Carr-Smith C, Carrillo MC et al. ( 2022 ) . Predictive immune biomarkers to safely discontinue nucleos (t)ide analogue treatment in HBeAg negative chronic hepatitis B (NUC-B study) . JOURNAL OF HEPATOLOGY . vol. 77 , S188 - S189 .

De Creus A, Slaets L, Fevery B, Van Gulck E, Zhou L, Van De Parre T, Van Den Broeke C, Dimitrova D et al. ( 2022 ) . Therapeutic vaccine JNJ-0535 induces a strong HBV-specific T-cell response in healthy adults and a modest response in chronic HBV-infected patients . JOURNAL OF HEPATOLOGY . vol. 77 , S72 - S73 .

Mohamed A, Kennedy P, Dolman G ( 2021 ) . PWE-38 The Impact of Metabolic Risk Factors on Treated Chronic Hepatitis B Patients . Gut . Conference: Posters vol. 70 , a122 - a124 .

Piermatteo L, Alkhatib M, D’Anna S, Malagnino V, Bertoli A, Andreassi E, Basile E, Iuvara A et al. ( 2021 ) . HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation . Biomedicines vol. 9 , ( 10 )

Wiggins BG, Pallett LJ, Li X, Davies SP, Amin OE, Gill US, Kucykowicz S, Patel AM et al. ( 2021 ) . The human liver microenvironment shapes the homing and function of CD4+ T-cell populations . Gut vol. 71 , ( 7 ) 1399 - 1411 .

Choudhry N, Drysdale K, Usai C, Leighton D, Sonagara V, Buchanan R, Nijjar M, Thomas S et al. ( 2021 ) . Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK . Frontiers in Medicine vol. 8 ,

Dolman GE, Koffas A, Phipps E, Kennedy PTF ( 2021 ) . Clinical and occupational health management of healthcare workers living with chronic hepatitis B: UK policy and international comparisons . Journal of Viral Hepatitis vol. 28 , ( 7 ) 976 - 981 .

Koffas A, Kumar M, Gill US, Jindal A, Kennedy PTF, Sarin SK ( 2021 ) . Chronic hepatitis B: the demise of the ‘inactive carrier’ phase . Hepatology International vol. 15 , ( 2 ) 290 - 300 .

Svicher V, Salpini R, Piermatteo L, Carioti L, Battisti A, Colagrossi L, Scutari R, Surdo M et al. ( 2020 ) . Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B . Gut vol. 70 , ( 12 ) 2337 - 2348 .

Lampertico P, Berg T, Buti M, Pathil A, Petersen J, Ryder SD, Zoulim F, Botros I et al. ( 2020 ) . Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study . Alimentary Pharmacology & Therapeutics vol. 52 , ( 3 ) 500 - 512 .

Jeffcote N, Freestone M, Heathcote C, Shaw J, Kennedy P ( 2020 ) . Agreement over content of case formulation in offender personality disorder pathway prison services . Criminal Behaviour and Mental Health Article cbm.2148 ,

Zeng G, Gill US, Kennedy PTF ( 2020 ) . Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis . Gut vol. 69 , ( 11 ) 1907 - 1912 .

Salpini R, Battisti A, Piermatteo L, Carioti L, Anastasiou OE, Gill US, Di Carlo D, Colagrossi L et al. ( 2020 ) . Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection . Emerging Microbes & Infections vol. 9 , ( 1 ) 928 - 939 .

Avellon A, Ala A, Diaz A, Domingo D, Gonzalez R, Hidalgo L, Kooner P, Loganathan S et al. ( 2020 ) . Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection . Journal of Medical Virology vol. 92 , ( 12 ) 3403 - 3411 .

Le Bert N, Gill US, Hong M, Kunasegaran K, Tan DZM, Ahmad R, Cheng Y, Dutertre C-A et al. ( 2020 ) . Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection . Gastroenterology vol. 159 , ( 2 ) 652 - 664 .

Koffas A, Petersen J, Kennedy PT ( 2020 ) . Reasons to consider early treatment in chronic hepatitis B patients . Antiviral Research vol. 177 ,

Koffas A, Kennedy PT ( 2020 ) . Hepatitis B e antigen‐positive chronic hepatitis B infection with minimal changes on liver biopsy: what to do next . Clinical Dilemmas in Viral Liver Disease , Wiley

Cornberg M, Lok AS, Terrault NA, Zoulim F, Faculty TEHTEC ( 2020 ) . Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference . Hepatology vol. 71 , ( 3 ) 1070 - 1092 .

Bigogno CM, Falahieh RR, Ho KMA, Jeffrey-Smith A, Jones M, Usai C, Battisti A, Gill U et al. ( 2020 ) . The genetic landscape of hepatitis delta virus infection . Clinical Medicine vol. 20 , ( Suppl 2 )

Bertoletti A, Gill US, Kennedy PTF ( 2020 ) . Early treatment of chronic hepatitis B in children: Everything to play for? . Journal of Hepatology vol. 72 , ( 4 ) 802 - 803 .

Dolman GE, Kennedy PTF ( 2020 ) . Hepatitis B reactivation: reducing the risk in patients with inflammatory bowel disease . Gut vol. 69 , ( 11 ) 2053 - 2054 .

Chan EKH, Aldhouse NVJ, Kitchen H, Pegram H, Kennedy PTF ( 2020 ) . A QUALITATIVE LITERATURE REVIEW TO BUILD A PATIENT-FOCUSED OUTCOME MEASUREMENT STRATEGY FOR CHRONIC HEPATITIS B . HEPATOLOGY . vol. 72 , 418A - 419A .

Agarwal K, Afdhal N, Coffin C, Fung S, Dusheiko G, Foster G, Elkhashab M, Tam E et al. ( 2020 ) . Liver toxicity in the Phase 2 Catalyst 206 trial of Inarigivir 400 mg daily added to a nucleoside in HBV EAg negative patients . JOURNAL OF HEPATOLOGY . vol. 73 , S125 - S125 .

Phillips S, Mistry S, Coombes J, Hadzhiolova T, Doornebal E, Harris N, Palma E, Riva A et al. ( 2020 ) . Osteopontin drives HBV replication and HBV-driven fibrogenesis and represents a novel therapeutic target to achieve functional cure in chronic hepatitis B . JOURNAL OF HEPATOLOGY . vol. 73 , S845 - S845 .

Gill US, Battisti A, Kennedy PTF ( 2019 ) . Emerging tools in the changing landscape of chronic hepatitis B management . Expert Review of Anti-infective Therapy vol. 17 , ( 12 ) 943 - 955 .

Cornberg M, Lok AS-F, Terrault NA, Zoulim F, Faculty E-AHTEC, Berg T, Brunetto MR, Buchholz S et al. ( 2019 ) . Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡ . Journal of Hepatology vol. 72 , ( 3 ) 539 - 557 .

Koffas A, Kennedy PT ( 2019 ) . Hepatitis B and D . Medicine vol. 47 , ( 11 ) 746 - 751 .

Bénéchet AP, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, Fumagalli V, Lusito E et al. ( 2019 ) . Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming . Nature vol. 574 , ( 7777 ) 200 - 205 .

Le Bert N, Salimzadeh L, Gill US, Dutertre CA, Facchetti F, Tan A, Hung M, Novikov N et al. ( 2019 ) . Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B . Journal of Hepatology

Dolman G, Theocharopoulos I, Kennedy P ( 2019 ) . PTU-089 Hepatitis B screening prior to rituximab and subsequent management to reduce the risk of reactivation . Gut . Conference: Posters vol. 68 ,

Svicher V, Salpini R, Battisti A, Colagrossi L, Piermatteo L, Surdo M, Cacciafesta V, Nuccitelli A et al. ( 2019 ) . GS-17-The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative disease: Implications for the treatment and management of CHB . Journal of Hepatology . vol. 70 , e83 - e84 .

Calvo AA, Ala A, Diaz A, Domingo D, Gonzalez R, Hidalgo L, Kooner P, Loganathan S et al. ( 2019 ) . THU-384-Clinical Performance of determine TM HBsAg 2 rapid test for hepatitis B detection . Journal of Hepatology . vol. 70 , e323 - e324 .

Koffas A, Gill U, Kennedy P ( 2019 ) . Hepatitis B: Prognosis and Treatment . Evidence‐based Gastroenterology and Hepatology 4e , Wiley

Khakpoor A, Ni Y, Chen A, Ho ZZ, Oei V, Yang N, Giri R, Chow JX et al. ( 2019 ) . Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection . Journal of Virology vol. 93 , ( 4 ) 10.1128/jvi.01457 - 10.1128/jvi.01418 .

Piermatteo L, Battisti A, Carioti L, Anastasiou O, Gill US, Colagrossi L, Bertoli A, Aragri M et al. ( 2019 ) . Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection . Digestive and Liver Disease . vol. 51 ,

Salpini R, Carioti L, Battisti A, Colagrossi L, Piermatteo L, Surdo M, Cacciafesta V, Nuccitelli A et al. ( 2019 ) . The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative chronic infection: implications for an altered cell homeostasis and metabolism . Digestive and Liver Disease . vol. 51 ,

Bertoletti A, Kennedy PTF ( 2019 ) . HBV antiviral immunity: not all CD8 T cells are born equal . Gut vol. 68 , ( 5 )

Gill US, Le Bert N, Kunasegaran K, Hansi N, Tan D, Peppa D, Maini MK, Bertoletti A et al. ( 2019 ) . GENE ONTOLOGY ENRICHMENT AND INGENUITY PATHWAY ANALYSIS REVEALS DIFFERENTIALLY IMMUNE REGULATED NETWORKS IN TREATED COMPARED TO UNTREATED CHRONIC HEPATITIS B PATIENTS . HEPATOLOGY . vol. 70 , 609A - 609A .

Buti M, Lampertico P, Lim Y-S, Agarwal K, Fung SK, Tsang O, Elkhashab M, Kao J-H et al. ( 2019 ) . SAFETY AND EFFICACY AT 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TDF USE . HEPATOLOGY . vol. 70 , 301A - 301A .

Piermatteo L, Battisti A, Carioti L, Anastasiou O, Gill US, Colagrossi L, Bertoli A, Aragri M et al. ( 2019 ) . Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels in vivo, hamper HBsAg secretion in vitro and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection . JOURNAL OF HEPATOLOGY . vol. 70 , E713 - E714 .

Gill US, Kennedy PTF ( 2019 ) . The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics . J Viral Hepat vol. 26 , ( 1 ) 4 - 15 .

KENNEDY P, HANSI N, Bertoletti A, Otano I ( 2018 ) . Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver . Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver.

KENNEDY PATRICK ( 2018 ) . PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection . Journal of Clinical Investigation vol. 128 , ( 10 ) 4573 - 4587 .

Chan HLY, Messinger D, Papatheodoridis GV, Cornberg M, Xie Q, Piratvisuth T, Ren H, Kennedy PT et al. ( 2018 ) . A baseline tool for predicting response to peginterferon alfa‐2a in HBeAg‐positive patients with chronic hepatitis B . Alimentary Pharmacology & Therapeutics vol. 48 , ( 5 ) 547 - 555 .

Foxler DE, Bridge KS, Foster JG, Grevitt P, Curry S, Shah KM, Davidson KM, Nagano A et al. ( 2018 ) . A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia . EMBO Mol Med

Koffas A, Dolman GE, Kennedy PT ( 2018 ) . Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians . Clinical Medicine vol. 18 , ( 3 ) 212 - 218 .

Dolman GE, Koffas A, Mason WS, Kennedy PT ( 2018 ) . Why, who and when to start treatment for chronic hepatitis B infection . Current Opinion in Virology vol. 30 , 39 - 47 .

Svicher V, Salpini R, Colagrossi L, Carlo DD, Battisti A, Piermatteo L, Hansi N, Silberstein FC et al. ( 2018 ) . FRI-272 Combination of HBV serological markers to predict the burden and productivity of intrahepatic HBV reservoir and disease progression in HBeAg negative Chronic Hepatitis B . Journal of Hepatology . vol. 68 ,

Colagrossi L, Salpini R, Gill US, Battisti A, Piermatteo L, Carlo DD, Hansi N, Silberstein FC et al. ( 2018 ) . FRI-277 Basal core promoter mutations as potential predictors of an enlarged intrahepatic HBV reservoir and enhanced cccDNA transcriptional activity in HBeAg negative chronic hepatitis B infection . Journal of Hepatology . vol. 68 ,

Salpini R, Battisti A, Carioti L, Carlo DD, Anastasiou O, Gill US, Colagrossi L, Bertoli A et al. ( 2018 ) . FRI-293 Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection . Journal of Hepatology . vol. 68 , s492 - s493 .

Salimzadeh L, Le Bert N, Gill US, Kennedy P, Samuel D, Novikov N, Frey C, Fletcher S et al. ( 2018 ) . PS-114 Exhaustion of virus-specific and total B cellpopulations by HBV infection . Journal of Hepatology . vol. 68 ,

Phillips S, Coombes J, Mistry S, Simonova M, Hadzhiolova T, Pavlova S, Katzarov K, Kennedy P et al. ( 2018 ) . SAT-378 Pro-fibrogenic mediator osteopontin is intimately involved in chronic hepatitis B and promotes cccDNA production . Journal of Hepatology . vol. 68 ,

Bert NL, Hong M, Tan D, Kunasegaran K, Cheng Y, Brecht E, Gill US, Frey C et al. ( 2018 ) . SAT-419 The impact of HBsAg on general and HBV-specific immunity . Journal of Hepatology . vol. 68 ,

Salpini R, Colagrossi L, Gill US, Battisti A, Piermatteo L, Hansi N, Perno CF, Kennedy PTF et al. ( 2018 ) . Combination of HBV serological markers can predict the burden and productivity of intrahepatic HBV reservoir and disease progression in HBeAg-negative chronic hepatitis B infection . Digestive and Liver Disease . vol. 50 ,

Colagrossi L, Salpini R, Gill US, Battisti A, Piermatteo L, Di Carlo D, Hansi N, Ceccherini-Silberstein F et al. ( 2018 ) . HBV reservoir and enhanced cccDNA transcriptional activity in HBeAg negative chronic hepatitis B . Digestive and Liver Disease . vol. 50 ,

Gill US, Pallett LJ, Kennedy PTF, Maini MK ( 2018 ) . Liver sampling: a vital window into HBV pathogenesis on the path to functional cure . Gut vol. 67 , ( 4 )

KENNEDY P ( 2018 ) . Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation . Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation vol. 128 , ( 2 ) 668 - 681 .

KENNEDY P ( 2018 ) . A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B . Annals of Gastroenterology vol. 31 , 1 - 20 .

KENNEDY P ( 2018 ) . Circulating and intrahepatic antiviral B cells are defective in hepatitis B . Circulating and intrahepatic antiviral B cells are defective in hepatitis B.

Salimzadeh L, Le Bert N, Gill US, Kennedy PT, Samuel D, Novikov N, Frey CR, Fletcher S et al. ( 2018 ) . Dysfunctional HBsAg-specific and modified global B cells in chronic Hepatitis B virus infection . JOURNAL OF VIRAL HEPATITIS . vol. 25 , 34 - 35 .

KENNEDY PATRICK ( 2018 ) . Fine needle aspirates comprehensively sample intrahepatic immunity . Fine needle aspirates comprehensively sample intrahepatic immunity

Gill US, Hansi N, Bert NL, Kunasegaran K, Dolman GE, Tan D, Tong W, Maini M et al. ( 2018 ) . HBV-specific T cell responses in low replicating inactive carrier patients are independent of Hepatitis B surface antigen load . JOURNAL OF HEPATOLOGY . vol. 68 , S793 - S794 .

Gill US, Pallett LJ, Thomas N, Burton AR, Stegmann KA, Kennedy PTF, Maini MK ( 2018 ) . Probing Novel HBV Therapies Using Fine Needle Aspirates to Sample Compartmentalised Liver-Resident Immunity and Hepatocytes . HEPATOLOGY . vol. 68 , 152A - 152A .

Gill US, Pallett LJ, Burton A, Stegmann K, Kennedy P, Maini M ( 2018 ) . Probing new HBV therapies using fine needle aspirates to sample compartmentalised liver-resident immunity and hepatocytes . JOURNAL OF HEPATOLOGY . vol. 68 , S793 - S793 .

Dolman G, Saleh H, Kemos P, Kennedy PTF ( 2018 ) . Quantitative Hepatitis B Surface Antigen (qHBsAg) Has Poor Performance As a Marker of High Risk Antenatal Chronic Hepatitis B (CHB) in a Multi-Ethnic Population . HEPATOLOGY . vol. 68 , 1187A - 1188A .

Le Bert N, Hong M, Tan D, Kunasegaran K, Cheng Y, Brecht E, Gill U, Frey C et al. ( 2018 ) . The impact of HBsAg on general and HBV-specific immunity . JOURNAL OF VIRAL HEPATITIS . vol. 25 , 35 - 35 .

Bertoletti A, Kennedy PTF, Durantel D ( 2017 ) . HBV infection and HCC: the ‘dangerous liaisons’ . Gut vol. 67 , ( 5 )

Singh HD, Otano I, Rombouts K, Singh KP, Peppa D, Gill US, Böttcher K, Kennedy PTF et al. ( 2017 ) . TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis . Scientific Reports vol. 7 , ( 1 )

Gill US, Kennedy PTF ( 2017 ) . Current therapeutic approaches for HBV infected patients . Journal of Hepatology vol. 67 , ( 2 ) 412 - 414 .

KENNEDY PATRICK ( 2017 ) . Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity . Journal of Hepatology vol. 67 , ( 4 ) 687 - 699 .

Pallett LJ, Davies J, Colbeck EJ, Robertson F, Hansi N, Easom NJW, Burton AR, Stegmann KA et al. ( 2017 ) . IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection . J Exp Med vol. 214 , ( 6 ) 1567 - 1580 .

Kennedy PTF, Litwin S, Dolman GE, Bertoletti A, Mason WS ( 2017 ) . Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks . Viruses vol. 9 , ( 5 )

Kennedy PTF, Bertoletti A, Mason WS ( 2017 ) . Reply . Gastroenterology vol. 152 , ( 5 ) 1246 - 1247 .

Gill US, Peppa D, Micco L, Singh HD, Le Bert N, Rivino L, Kunasegaran K, Tan D et al. ( 2017 ) . Effect of in-vivo hepatitis B viral load suppression after interferon exposure on natural killer and T-cell responsiveness . vol. 389 , Elsevier

Salpini R, Battisti A, Anastasiou O, Gill U, Colagrossi L, Bertoli A, Fabeni L, Fini V et al. ( 2017 ) . In HBeAg-negative chronic HBV infection, HBsAg levels profoundly differ among HBV-genotypes and can be affected by the extent of HBsAg variability: Can quantitative HBsAg truly reflect intra-hepatic HBV reservoir? . Digestive and Liver Disease . vol. 49 ,

Salpini R, Colagrossi L, Battisti A, Hansi N, Perno CF, Gill US, Kennedy PTF, Svicher V ( 2017 ) . Peripheral and intrahepatic virological phenotyping in HBeAg negative Chronic Hepatitis B to evaluate risk of disease progression and HCC in the “grey-zone” viral load cohort: Can grey-zone patients be candidate to treatment? . Digestive and Liver Disease . vol. 49 ,

Salpini R, Battisti A, Anastasiou O, Gill U, Colagrossi L, Bertoli A, Fabeni L, Fini V et al. ( 2017 ) . FRI-133 In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir? . Journal of Hepatology . vol. 66 ,

Gill US, Bert NL, Kunasegaran K, Khakpoor A, Hansi N, Tan D, Rivino L, Singh HD et al. ( 2017 ) . FRI-297 Transcriptome profiles of NK and T cells associated with immune control in chronic hepatitis B patients treated with pegylated interferon alpha-nucleos(t)ide analogue sequential therapy . Journal of Hepatology . vol. 66 ,

Gill US, Hansi NK, Le Bert N, Kunasegaran K, Tan D, Dolman GE, Payaniandy L, Tong W et al. ( 2017 ) . HBV-specific T cell immunity in inactive carrier patients is independent of Hepatitis B surface antigen load . HEPATOLOGY . vol. 66 , 787A - 788A .

Salimzadeh L, Bert NL, Gill US, Kennedy PT, Samuel D, Novikov N, Pflanz S, Frey CR et al. ( 2017 ) . PS-049 Modifications of virus-specific and total B cell populations by hepatitis B virus infection . Journal of Hepatology . vol. 66 , s28 - s29 .

KENNEDY PATRICK ( 2017 ) . Reply . Gastroenterology vol. 152 , ( 5 ) 1246 - 1247 .

Le Bert N, Rivino L, Gill US, Cheng Y, Kunasegaran K, Tan DZ, Becht E, Hansi NK et al. ( 2017 ) . SAT-152 PD-1+ CD8+ T cells as immunological biomarkers for the safe discontinuation of anti-viral therapy in chronic hepatitis B . Journal of Hepatology . vol. 66 ,

Svicher V, Salpini R, Colagrossi L, Battisti A, Piermatteo L, Hansi N, Perno CF, Gill US et al. ( 2017 ) . SAT-186 Peripheral and intrahepatic virological phenotyping in eAg negative chronic hepatitis B to evaluate risk of disease progression and hepatocellular carcinoma in the “grey-zone” viral load cohort . Journal of Hepatology . vol. 66 ,

Gill US, Le Bert N, Kunasegaran K, Khakpoor A, Hansi NK, Tan D, Rivino L, Singh HD et al. ( 2017 ) . Transcriptome profiles of NK and T cells regulating immune control in chronic hepatitis B, proximate to patients treated with Pegylated Interferon alpha-Nucleos(t)ide analogue (NA) sequential therapy compared to de novo NA therapy . HEPATOLOGY . vol. 66 , 70A - 70A .

KENNEDY P ( 2016 ) . T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System . T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System

Hansi N, Gill U, Kennedy P ( 2016 ) . Chronic Hepatitis B . Liver Disease in Clinical Practice , Springer Nature

Hansi N, Troke P, Gill, Agarwal K, Aldersley M, Al-Shamma S, Brown A, Cobbold J et al. ( 2016 ) . PTH-107 Chronic Hepatitis B Management The UK: A National Survey of Current Practice Following Nice Guidance . Gut . vol. 65 ,

Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK, Kennedy PTF ( 2016 ) . Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo . PLOS Pathogens vol. 12 , ( 8 ) e1005788 - e1005788 .

Schurich A, Pallett LJ, Jajbhay D, Wijngaarden J, Otano I, GIll US, Hansi N, Kennedy PT et al. ( 2016 ) . Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host . Cell Reports vol. 16 , ( 5 ) 1243 - 1252 .

Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, Hong ML, Naik S et al. ( 2016 ) . HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant . Gastroenterology

Stegmann KA, Robertson F, Hansi N, Gill U, Pallant C, Christophides T, Pallett LJ, Peppa D et al. ( 2016 ) . CXCR6 marks a novel subset of T-betloEomeshi natural killer cells residing in human liver . Scientific Reports vol. 6 , 26157 - 26157 .

Chan HL-Y, Messinger D, Papatheodoridis GV, Cornberg M, Xie Q, Piratvisuth T, Ren H, Kennedy P et al. ( 2016 ) . FRI-117 A Genotype-Specific Baseline Score to Predict Post-Treatment Response to Peginterferon Alfa-2a in HBeAg-Positive Patients with Hepatitis B Virus Genotype B or C Infection . Journal of Hepatology . vol. 64 , s589 - s590 .

Lampertico P, Messinger D, Cornberg M, Brunetto M, Petersen J, Kennedy P, Asselah T, Rothe V et al. ( 2016 ) . FRI-138 A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B . Journal of Hepatology . vol. 64 , s599 - s600 .

Rivino L, Le Bert N, Gill U, Cheng Y, Kunasegaran K, Tan D, Koh S, Hansi N et al. ( 2016 ) . PS056 An Immunological Biomarker to Predict Hepatic Flares upon Nuc Therapy Discontinuation in Chronic Hepatitis B . Journal of Hepatology . vol. 64 , s164 - s165 .

Svicher V, Salpini R, Gill US, Colagrossi L, Hansi NK, Perno CF, Kennedy PT ( 2016 ) . Peripheral and intrahepatic virological phenotyping in eAg negative Chronic Hepatitis B underlines the limitations of current treatment thresholds in low to moderate viraemic patients . HEPATOLOGY . vol. 64 , 308A - 308A .

Le Bert N, Rivino L, Cheng Y, Tan D, Newell E, Arvey A, Kennedy P, Pflanz S et al. ( 2016 ) . THU-201 Application of Mass Cytometry Time of Flight (CYTOF) for Systematic Characterization of PBMC Phenotypes Associated with HBSAG Serum Levels in Chronic HBV Patients . Journal of Hepatology . vol. 64 , s393 - s394 .

Abbara A, Kennedy P, Gordon F, Brown A, Goldin R, Main J, Thomas H, Thursz M ( 2015 ) . PTU-049 Rate of disease progression and the influence of co-factors in hepatitis C virus as determined by interval liver biopsy . Gut vol. 59 , ( Suppl 1 )

Ghani R, Javaid A, Marley R, Lindsay J, Kennedy PT, Foster GR ( 2010 ) . PWE-047 Evaluation of PEG-IFN in an ethnically diverse HBV-infected population: 50% of treated patients derive long-term benefit . Gut . vol. 59 ,

Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, Kennedy PT, Dusheiko G, Hill-Cawthorne G et al. ( 2015 ) . Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom . Value in Health vol. 18 , ( 6 ) 800 - 809 .

Rivino L, Van Den Berg M, Gill, Le Bert N, Koh S, Hansi N, Newell E, Foster G et al. ( 2015 ) . PTU-103 Characterisation of the immune profile in chronic hepatitis b patients following nucleos(t)ide discontinuation by cytof mass cytometry . Gut . vol. 64 ,

Hansi N, Gill, Banerjee M, Naik S, Tong W, Foster G, Carey I, Kennedy P ( 2015 ) . PTU-106 Identifying true immune-tolerant disease in children and young adults with chb using quantified hepatitis b surface antigen levels . Gut . vol. 64 ,

Hansi N, Gill, Banerjee M, Naik S, Tong W, Foster G, Carey I, Kennedy P ( 2015 ) . PTU-107 Defining the low-risk inactive carrier in chronic hepatitis b with qhbsag: do the same rules apply in children and young adults? . Gut . vol. 64 ,

Gill, Peppa D, Micco L, Singh H, Foster G, Maini M, Kennedy P ( 2015 ) . PTU-116 Functional immune restoration correlates with HBSAG decline and may predict treatment response on sequential NUC therapy in CHB . Gut . vol. 64 ,

Gill, Hansi N, Payaniandy L, Schulz J, Payaniandy D, Alazawi W, Dearden J, Kallis Y et al. ( 2015 ) . PTU-117 Sequential NUC therapy following pegylated interferon provides a greater decline in HBSAG and potentially offers a treatment advantage over current therapies . Gut . vol. 64 ,

Pallett LJ, Gill US, Quaglia A, Sinclair LV, Jover-Cobos M, Schurich A, Singh KP, Thomas N et al. ( 2015 ) . Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells . Nat Med vol. 21 , ( 6 ) 591 - 600 .

Bertoletti A, Kennedy PT ( 2015 ) . The immune tolerant phase of chronic HBV infection: new perspectives on an old concept . Cell Mol Immunol vol. 12 , ( 3 ) 258 - 263 .

Gill US, Kennedy PT ( 2015 ) . New insights in the management of chronic hepatitis B . Clinical Medicine vol. 15 , ( 2 ) 191 - 196 .

Rivino L, Van Den Berg M, Le Bert N, Koh S, Gill US, Hansi NK, Foster GR, Bertoletti A et al. ( 2015 ) . P0474 : Characterisation of the immune profiles of chronic hepatitis B patients following NUC discontinuation by cyTOF mass cytometry . Journal of Hepatology . vol. 62 ,

Huang W-C, Peppa D, Easom N, Tang X-Z, Singh H, Fusai G, Rosenberg W, Ghosh I et al. ( 2015 ) . P0478 : NKG2D-dependent cross-talk between NK cells and CD4 T cells in chronic hepatitis B . Journal of Hepatology . vol. 62 ,

Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PT ( 2015 ) . P0485 : Functional immune restoration correlates with HBsAg decline and may predict treatment response on sequential NUC therapy in chronic hepatitis B . Journal of Hepatology . vol. 62 ,

Mathew S, Petrova M, Hendy J, de Lusignan S, Zamani J, Tiwari R, Nicholls M, Kennedy P et al. ( 2015 ) . P1260 : Perceptions of viral hepatitis testing in migrant communities and the primary care physicians that serve them . Journal of Hepatology . vol. 62 ,

Bouzidi KE, Elamin W, Kranzer K, Irish DN, Ferns B, Kennedy P, Rosenberg W, Dusheiko G et al. ( 2015 ) . Hepatitis delta virus testing, epidemiology and management: A multicentre cross-sectional study of patients in London . Journal of Clinical Virology vol. 66 , 33 - 37 .

Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJW, Barr DA, Kallis YN, Marley RTC et al. ( 2015 ) . Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? . J Infect Dis vol. 211 , ( 3 ) 374 - 382 .

Gill US, Rivino L, Le Bert N, Kunasegaran K, Tan D, Koh S, Van den Berg M, Cheng Y et al. ( 2015 ) . Characterisation of the immune profile in Chronic Hepatitis B, with CyTOF, to identify biomarkers of immune control following NUC therapy discontinuation . HEPATOLOGY . vol. 62 , 294A - 294A .

Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK, Kennedy PT ( 2015 ) . NK cell function is restored with sequential NUC therapy and correlates with treatment response in Chronic Hepatitis B . HEPATOLOGY . vol. 62 , 1001A - 1002A .

Hansi NK, Seipt CC, Gill US, Naik S, Tong W, Foster GR, Carey I, Kennedy PT ( 2015 ) . Quantitative Hepatitis B surface antigen (qHBsAg) may define low-risk inactive carriers of CHB: Can this provide a framework for better management across all age-groups? . HEPATOLOGY . vol. 62 , 976A - 977A .

Gill US, Kennedy PTF ( 2014 ) . Chronic hepatitis B virus in young adults: the need for new approaches to management . Expert Rev Anti Infect Ther vol. 12 , ( 9 ) 1045 - 1053 .

Jo J, Tan AT, Ussher JE, Sandalova E, Tang X-Z, Tan-Garcia A, To N, Hong M et al. ( 2014 ) . Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver . PLoS Pathog vol. 10 , ( 6 )

Kennedy PTF, Gill US, Bertoletti A, Mason WS ( 2014 ) . O106 CLONAL HEPATOCYTE REPOPULATION IN THE YOUNG ADULT HBV INFECTED LIVER CHALLENGES THE CONCEPT OF A GENERIC IMMUNE TOLERANT DISEASE PHASE . Journal of Hepatology . vol. 60 ,

Pallett LJ, Haniffa M, Schurich A, Gill U, Davies N, Jover-Cobos M, Das A, Gilson R et al. ( 2014 ) . P132 MYELOID-DERIVED SUPPRESSOR CELLS MEDIATE IMMUNOTOLERANCE IN CHRONIC HEPATITIS B (CHB) THROUGH ARGININE DEPRIVATION . Journal of Hepatology . vol. 60 ,

Huang W-C, Peppa D, Easom N, Tan X-Z, Chang C, Trowsdale J, Gill U, Kennedy P et al. ( 2014 ) . P137 THE EXPRESSION OF NKG2D-LIGANDS BY ACTIVATED CD4 T CELLS RENDERS THEM SUSCEPTIBLE TO NK CELL REGULATION IN CHRONIC HEPATITIS B (CHB) . Journal of Hepatology . vol. 60 ,

Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PTF ( 2014 ) . P152 SEQUENTIAL NUC THERAPY FOLLOWING PEGYLATED INTERFERON-ALPHA EXPOSURE RESTORES INNATE IMMUNE RESPONSES CONFERRING A TREATMENT ADVANTAGE OVER NUC MONOTHERAPY IN CHRONIC HEPATITIS B . Journal of Hepatology . vol. 60 ,

Lubowiecki M, Pallmer K, Jajbhay D, Pallett LJ, Gill U, Kennedy PT, Maini M, Schurich A ( 2014 ) . P159 CO-INHIBITORY RECEPTOR LAG-3 POSITIVE CD8 T CELLS PRODUCE IMMUNOSUPPRESSIVE TGF-β IN CHRONIC HBV . Journal of Hepatology . vol. 60 , s118 - s119 .

Pallett L, Gill U, Jover-Cobos M, Schurich A, Singh K, Thomas N, Das A, Chen A et al. ( 2014 ) . Arginase-dependent metabolic regulation of hepatic immunopathology by myeloid-derived suppressor cells . IMMUNOLOGY vol. 143 , 154 - 154 .

Kennedy PT, Gill US, Chen A, Litwin S, Bertoletti A, Mason W ( 2014 ) . Clonal Hepatocyte expansion in the young adult HBV infected liver is at odds with the concept of a generic immune tolerant disease phase: can additional clinical parameters distinguish disease phase? . HEPATOLOGY . vol. 60 , 1032A - 1033A .

Gill US, Peppa D, Singh HD, Micco L, Foster GR, Maini MK, Kennedy PT ( 2014 ) . Functional innate immune responses are restored with sequential NUC therapy following Pegylated Interferon-Alpha exposure and not with NUC monotherapy in Chronic Hepatitis B . HEPATOLOGY . vol. 60 , 1020A - 1021A .

Hansi NK, Gill US, Banerjee A, Surendraraj N, Patel C, Naik S, Foster GR, Kennedy PT ( 2014 ) . High levels of Hepatitis B surface antigen (HBsAg) can exclude significant fibrosis and distinguishes true 'immune-tolerance' in children and young adults with Chronic Hepatitis B . HEPATOLOGY . vol. 60 , 985A - 986A .

Lubowiecki M, Pallmer K, Jajbhay D, Pallett LJ, Gill U, Kennedy PT, Maini MK, Schurich A ( 2013 ) . Co-inhibitory receptor LAG-3 positive CD8 T cells produce immunosuppressive TGF-β in chronic HBV . IMMUNOLOGY . vol. 140 , 145 - 145 .

Gill US, Patel C, Naik S, Dearden J, Kallis YN, Kooner P, Marley R, Aleong J-AC et al. ( 2013 ) . Collagen proportionate area but not Ishak fibrosis stage on liver biopsy correlates with age in Chronic Hepatitis B infected young adults . HEPATOLOGY . vol. 58 , 427A - 428A .

Chen A, Gill US, Ikin CR, Aleong J-AC, Foster GR, Kennedy PT ( 2013 ) . Differential Hepatitis B virus core nuclear/cytoplasmic staining is a marker of longevity of chronic infection but not disease phase . HEPATOLOGY . vol. 58 , 423A - 424A .

Pallett LJ, Haniffa M, Jover-Cobos M, Schurich A, Das A, Gill U, Davies N, Ghosh I et al. ( 2013 ) . Expansion of arginase-expressing myeloid-derived suppressor cells in hepatotropic viral infections . IMMUNOLOGY . vol. 140 , 97 - 97 .

Gill US, Zissimopoulos A, Al-shamma S, Burke K, McPhail M, Barr D, Ross V, Kallis Y et al. ( 2013 ) . FRAX SCORE IN THE ASSESSMENT OF BONE MINERAL DENSITY CHANGES IN TENOFOVIR TREATED CHRONIC HEPATITIS B PATIENTS . GUT . vol. 62 , A190 - A190 .

Alazawi W, Abeysekera K, Dearden J, Glynn M, Kallis Y, Kennedy P, Marley R, Foster GR et al. ( 2013 ) . IMPLEMENTING EASL & AASLD GUIDELINES FOR HEPATOCELLULAR CARCINOMA SCREENING IS COST-EFFECTIVE IN LONDON'S ETHNICALLY DIVERSE POPULATION . JOURNAL OF HEPATOLOGY . vol. 58 , S397 - S397 .

Gill US, Payaniandy L, Payaniandy D, Schulz J, Ross VA, Kallis YN, Kooner P, Marley RTC et al. ( 2013 ) . INDUCTION MAINTENANCE THERAPY IN CHRONIC HEPATITIS B; STEP-DOWN FROM COMBINATION LAMIVUDINE AND TENOFOVIR TO LAMIVUDINE MONOTHERAPY - A POTENTIAL NEW TREATMENT STRATEGY . JOURNAL OF HEPATOLOGY . vol. 58 , S302 - S302 .

Gehring AJ, Haniffa M, Kennedy PT, Ho ZZ, Boni C, Shin A, Banu N, Chia A et al. ( 2013 ) . Mobilizing monocytes to cross-present circulating viral antigen in chronic infection . JOURNAL OF CLINICAL INVESTIGATION vol. 123 , ( 9 ) 3766 - 3776 .

Chen A, Schurich A, Aleong J-AC, Trivedi K, Gill U, Peppa D, Kennedy P, Bertoletti A et al. ( 2013 ) . PROBING HEPATIC ANTIGEN PRESENTATION IN PATIENTS WITH CHRONIC HBV INFECTION . JOURNAL OF HEPATOLOGY . vol. 58 , S136 - S136 .

Gill US, Payaniandy L, Schulz J, Payaniandy D, Ross V, Kallis Y, Kooner P, Marley R et al. ( 2013 ) . SEQUENTIAL ORAL ANTI-VIRAL THERAPY FOLLOWING PEGYLATED-INTERFERON-ALPHA FAILURE SIGNIFICANTLY INCREASES HBSAG DECLINE . GUT . vol. 62 , A189 - A190 .

Gill US, Peppa D, Micco L, Foster GR, Maini MK, Kennedy PT ( 2013 ) . Sustained restoration of innate immune responses and sAg decline in sequential NUC therapy following failed Pegylated-Interferon-α therapy in Chronic Hepatitis B . HEPATOLOGY . vol. 58 , 416A - 417A .

Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, Nastouli E, Tanwar S et al. ( 2013 ) . The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells . PLOS PATHOGENS vol. 9 , ( 3 ) Article ARTN e1003208 ,

Peppa D, Gill US, Reynolds G, Easom NJW, Pallett LJ, Schurich A, Micco L, Nebbia G et al. ( 2013 ) . Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion . JOURNAL OF EXPERIMENTAL MEDICINE vol. 210 , ( 1 ) 99 - 114 .

Kennedy PTF, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, Naik S, Foster GR et al. ( 2012 ) . Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B . Gastroenterology vol. 143 , ( 3 ) 637 - 645 .

Vergis N, Antoniades CG, Zingarelli V, Abeles RD, Ma Y, Shawcross D, Janmohamed A, Patch D et al. ( 2012 ) . PTU-016a Functional defects in circulating monocytes may contribute to susceptibility to infection in alcoholic hepatitis . Gut vol. 61 , ( Suppl 2 )

Gill U, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster G, Maini M et al. ( 2012 ) . Mo1837 Maximal Boosting of Innate Immunity During Pegylated Interferon-Aplha Therapy is Reached at 48 Weeks in E-Antigen Positive Chronic Hepatitis B . Gastroenterology vol. 142 , ( 5 ) s - 696 .

Vergis N, Antoniades CG, Zingarelli V, Abeles RD, Ma Y, Shawcross D, Patch D, Rosenberg W et al. ( 2012 ) . 99 FUNCTIONAL DEFECTS IN CIRCULATING MONOCYTES MAY CONTRIBUTE TO INCREASED SUSCEPTIBILTY TO INFECTION IN ALCOHOLIC HEPATITIS . Journal of Hepatology . vol. 56 ,

Patel C, Gill U, Alazawi W, Shaw P, Alstead EM, Kallis Y, Kooner P, Marley R et al. ( 2012 ) . Benchmarking disease activity and progression in Chronic Hepatitis B infected young adults . HEPATOLOGY . vol. 56 , 362A - 362A .

Gill US, Payaniandy L, Schulz J, Ross V, Kallis Y, Kooner P, Marley R, Ushiro-Lumb I et al. ( 2012 ) . CAN A 3-MONTH "STOPPING RULE" FOR PEGYLATED-INTERFERON-α BE APPLIED TO A UK POPULATION OF CHRONIC HEPATITIS B INFECTED PATIENTS OF MIXED GENOTYPE? . GUT vol. 61 , A145 - A145 .

Cunningham ME, Schulz J, Payaniandy L, Kallis Y, Kennedy P, Kooner P, Marley R, Foster GR ( 2012 ) . EARLY EXPERIENCE WITH TELAPREVIR FOR PATIENTS WITH ADVANCED FIBROSIS OR CIRRHOSIS . GUT vol. 61 , A141 - A141 .

Patel C, Gill US, Alazawi W, Shaw P, Alstead E, Kallis Y, Kooner P, Marley R et al. ( 2012 ) . EVALUATION OF LIVER FIBROSIS IN YOUNG ADULT PATIENTS WITH CHRONIC HEPATITIS B VIRUS . GUT vol. 61 , A133 - A133 .

Gill U, Zissimopoulos A, Al-Shamma S, Burke KB, Ross VA, Kallis Y, Kooner P, Marley R et al. ( 2012 ) . FRAX score in the assessment of Bone Mineral Density changes in Tenofovir treated Chronic Hepatitis B patients: comparison with bone biochemistry and DEXA scanning . HEPATOLOGY . vol. 56 , 201A - 201A .

Kennedy P, Prasad PB, Boyer J ( 2012 ) . Hepatobiliary sarcoidosis . Sarcoidosis ,

Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, Chen A, Blair P et al. ( 2012 ) . IL-10-Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection . JOURNAL OF IMMUNOLOGY vol. 189 , ( 8 ) 3925 - 3935 .

Liu M, Miao T, Zhu H, Symonds ALJ, Li L, Schurich A, Maini MK, Zhang J et al. ( 2012 ) . IL-2-Engineered nano-APC Effectively Activates Viral Antigen-Mediated T Cell Responses from Chronic Hepatitis B Virus-Infected Patients . JOURNAL OF IMMUNOLOGY vol. 188 , ( 3 ) 1534 - 1543 .

Gill US, Payaniandy L, Payaniandy D, Schulz J, Ross V, Kallis Y, Kooner P, Marley R et al. ( 2012 ) . INDUCTION MAINTENANCE TREATMENT IN CHRONIC HEPATITIS B; STEP-DOWN FROM TENOFOVIR AND LAMIVUDINE TO LAMIVUDINE MONOTHERAPY IS EFFECTIVE . GUT vol. 61 , A145 - A145 .

Gill US, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster GR, Maini MK et al. ( 2012 ) . MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-APLHA THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B . JOURNAL OF HEPATOLOGY . vol. 56 , S175 - S175 .

Gill US, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster GR, Maini MK et al. ( 2012 ) . MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-α THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B . GUT vol. 61 , A145 - A146 .

Gill U, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster G, Maini M et al. ( 2012 ) . Maximal Boosting of Innate Immunity During Pegylated Interferon-Aplha Therapy is Reached at 48 Weeks in E-Antigen Positive Chronic Hepatitis B . GASTROENTEROLOGY . vol. 142 , S696 - S696 .

Ji C, Sastry KSR, Tiefenthaler G, Cano J, Tang T, Ho ZZ, Teoh D, Bohini S et al. ( 2012 ) . Targeted Delivery of Interferon-α to Hepatitis B Virus-Infected Cells Using T-Cell Receptor-Like Antibodies . HEPATOLOGY vol. 56 , ( 6 ) 2027 - 2038 .

Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y, Rosenberg W, Dusheiko G et al. ( 2012 ) . Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection . PLOS ONE vol. 7 , ( 10 ) Article ARTN e47648 ,

Malik R, Kennedy P, Suri D, Brown A, Goldin R, Main J, Thomas H, Thursz M ( 2011 ) . The Role of Liver Fibrosis Assessment in the Management of Patients with Chronic Hepatitis B Infection: Lessons Learned from a Single Centre Experience . Hepatitis Research and Treatment vol. 2011 , ( 1 )

Gill U, Al-Shamma S, Burke KB, Ross VA, Marley R, Kooner P, Foster GR, Kennedy PT ( 2011 ) . BONE MINERAL DENSITY LOSS IN TENOFOVIR TREATED CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IS A CONSEQUENCE OF VITAMIN D DEFICIENCY AND NOT TENOFOVIR THERAPY . HEPATOLOGY . vol. 54 , 1012A - 1012A .

Kennedy PT, Sandalova E, Jo J, Gill U, Li L, Ushiro-Lumb I, Naik S, Foster GR et al. ( 2011 ) . IMMUNOLOGICAL ANALYSIS AND CLINICAL PROFILE OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN THE YOUNGER PATIENT . HEPATOLOGY . vol. 54 , 1092A - 1093A .

Gill US, Al-shamma S, Burke K, Ross V, Marley RTC, Kooner P, Foster GR, Kennedy PTF ( 2011 ) . P61 Bone mineral density loss in tenofovir treated Chronic Hepatitis B Virus (HBV) patients is a consequence of Vitamin D deficiency and not Tenofovir therapy . Gut vol. 60 , ( Suppl 2 )

Kennedy PTF, Sandalova E, Jo J, Gill US, Li L, Ushiro-Lumb I, Naik S, Foster GR et al. ( 2011 ) . P62 Immunological analysis and clinical profile of Chronic Hepatitis B Virus (HBV) infection in the younger patient . Gut vol. 60 , ( Suppl 2 )

Glyn FJ, Gill U, Alazawi W, Ross V, Kooner P, Marley R, Foster G, Kennedy PT ( 2011 ) . Efficacy of Combination Tenofovir Plus Lamivudine Versus Tenofovir Monotherapy in Patients With Chronic Hepatitis B Virus . Gastroenterology vol. 140 , ( 5 ) s - 455 .

Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, Nebbia G, Kennedy PTF et al. ( 2011 ) . Role of the Coinhibitory Receptor Cytotoxic T Lymphocyte Antigen-4 on Apoptosis-Prone CD8 T Cells in Persistent Hepatitis B Virus Infection . HEPATOLOGY vol. 53 , ( 5 ) 1494 - 1503 .

Gunawan AS, Gill U, Glyn FJ, Kooner P, Marley R, Ushiro-Lumb I, Foster G, Kennedy PT ( 2011 ) . Utility of HBsAg Quantification in Developing an Individualised Approach to the Management of Chronic Hepatitis B Virus in Clinical Practice . Gastroenterology vol. 140 , ( 5 ) s - 458 .

Patel C, Gill US, Glyn F, Naik S, Foster GR, Kennedy PTF ( 2011 ) . CHRONIC HBV INFECTION: ASSESSMENT AND MANAGEMENT OF DISEASE IN A YOUNG ADULT CLINIC . GUT . vol. 60 ,

Glyn F, Gill US, Alazawi W, Ross V, Kooner P, Marley R, Foster GR, Kennedy PTF ( 2011 ) . EFFICACY OF COMBINATION TENOFOVIR PLUS LAMIVUDINE VERSUS TENOFOVIR MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS . GUT . vol. 60 , A231 - A231 .

Gill US, Al-Shamma S, Burke K, Ross V, Marley R, Kooner P, Foster GR, Kennedy PTF ( 2011 ) . FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT? . GUT . vol. 60 ,

Gill U, Micco L, Li L, Peppa D, Ushiro-Lumb I, Foster GR, Maini MK, Kennedy PTF ( 2011 ) . PEGYLATED INTERFERON A MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION . GUT . vol. 60 , A232 - A232 .

Gunawan A, Gill US, Glyn F, Kooner P, Marley R, Ushiro-Lumb I, Foster GR, Kennedy PTF ( 2011 ) . UTILITY OF HBSAG QUANTIFICATION IN DEVELOPING AN INDIVIDUALISED APPROACH TO THE MANAGEMENT OF CHRONIC HEPATITIS B VIRUS IN CLINICAL PRACTICE . GUT . vol. 60 ,

Sastry KSR, Too CT, Kaur K, Gehring AJ, Low L, Javiad A, Pollicino T, Li L et al. ( 2011 ) . Targeting Hepatitis B Virus-Infected Cells with a T-Cell Receptor-Like Antibody . J VIROL vol. 85 , ( 5 ) 1935 - 1942 .

Schurich A, Khanna P, Lubowiecki M, Lopes AR, Peppa D, Micco L, Nebbia G, Singh H et al. ( 2011 ) . ALTERING CO-INHIBITORY AND CO-STIMULATORY PATHWAYS TO RESTORE ANTI-VIRAL T CELL RESPONSES IN CHRONIC HBV INFECTION . JOURNAL OF HEPATOLOGY . vol. 54 , S125 - S125 .

Glyn FJ, Gill U, Alazawi W, Ross V, Kooner P, Marley R, Foster G, Kennedy PT ( 2011 ) . Efficacy of Combination Tenofovir Plus Lamivudine Versus Tenofovir Monotherapy in Patients With Chronic Hepatitis B Virus . GASTROENTEROLOGY . vol. 140 , S455 - S455 .

Gill US, Al-Shamma S, Burke K, Ross V, Kooner P, Marley R, Foster GR, Kennedy PTF ( 2011 ) . FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT? . JOURNAL OF HEPATOLOGY . vol. 54 , S286 - S286 .

Gill US, Micco L, Li L, Peppa D, Ushiro-Lumb I, Foster GR, Maini MK, Kennedy PTF ( 2011 ) . PEGYLATED INTERFERON ALPHA MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION . JOURNAL OF HEPATOLOGY . vol. 54 , S32 - S32 .

Nebbia G, Peppa D, Schurich A, Khanna P, Singh H, Rosenberg W, Dusheiko G, Gilson R et al. ( 2011 ) . Role of the TIM-3/Galectin-9 pathway in chronic hepatitis B infection . IMMUNOLOGY . vol. 135 , 69 - 69 .

Peppa D, Gill U, Micco L, Schurich A, Nebbia G, Singh H, Rosenberg W, Gilson R et al. ( 2011 ) . Susceptibility of T cells to death ligand-mediated deletion in the liver of chronic hepatitis B virus (CHB) infected patients . IMMUNOLOGY . vol. 135 , 60 - 60 .

Ji C, Seetharama S, Tang T, Tei TC, Tiefenthaler G, Lopatin U, Sankuratri S, Ma H et al. ( 2011 ) . TARGETED DELIVERY OF ANTI-VIRAL CYTOKINE TO HBV-INFECTED CELLS USING T CELL RECEPTOR-LIKE ANTIBODIES . JOURNAL OF HEPATOLOGY . vol. 54 , S32 - S33 .

Gunawan AS, Gill U, Glyn FJ, Kooner P, Marley R, Ushiro-Lumb I, Foster G, Kennedy PT ( 2011 ) . Utility of HBsAg Quantification in Developing an Individualised Approach to the Management of Chronic Hepatitis B Virus in Clinical Practice . GASTROENTEROLOGY . vol. 140 , S458 - S458 .

Peppa D, Micco L, Javaid A, Kennedy PTF, Schurich A, Dunn C, Pallant C, Ellis G et al. ( 2010 ) . Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection . PLOS PATHOG vol. 6 , ( 12 ) Article e1001227 ,

Ashrafi GH, Grinfeld E, Montague P, Forster T, Ross A, Ghazal P, Scott F, Breuer J et al. ( 2010 ) . Assessment of transcriptomal analysis of varicella-zoster-virus gene expression in patients with and without post-herpetic neuralgia . Virus Genes vol. 41 , ( 2 ) 192 - 201 .

Kennedy PTF, Russo E, Kumar N, Powell N, Bansi D, Thillainayagam A, Vlavianos P, Westaby D ( 2010 ) . The safety and utility of prophylactic pancreatic duct stents in the prevention of post-ERCP pancreatitis: an analysis of practice in a single UK tertiary referral center . Surgical Endoscopy vol. 24 , ( 8 ) 1923 - 1928 .

Kennedy PTF, Gehring AJ, Nowbath A, Selden C, Quaglia A, Dhillon A, Dusheiko G, Bertoletti A ( 2008 ) . The expression and function of NKG2D molecule on intrahepatic CD8+ T cells in chronic viral hepatitis . Journal of Viral Hepatitis vol. 15 , ( 12 ) 901 - 909 .

Das A, Hoare M, Davies N, Lopes AR, Dunn C, Kennedy PTF, Alexander G, Finney H et al. ( 2008 ) . Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection . Journal of Experimental Medicine vol. 205 , ( 9 ) 2111 - 2124 .

Kennedy PT, Phillips N, Chandrasekhar J, Jacobs R, Jacobs M, Dusheiko G ( 2008 ) . Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping . Liver International vol. 28 , ( 5 ) 699 - 704 .

PATRICK KENNEDY, KINGSTON AL ( 2008 ) . NICE guidelines and a treatment algorithm for the management of chronic hepatitis B: a review of 12 years experience in west London . NICE guidelines and a treatment algorithm for the management of chronic hepatitis B: a review of 12 years experience in west London

Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR et al. ( 2007 ) . Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage . Journal of Experimental Medicine vol. 204 , ( 3 ) 667 - 680 .

Gehring AJ, Sun D, Kennedy PTF, Hoen EN-T, Lim SG, Wasser S, Selden C, Maini MK et al. ( 2007 ) . The Level of Viral Antigen Presented by Hepatocytes Influences CD8 T-Cell Function . Journal of Virology vol. 81 , ( 6 ) 2940 - 2949 .

Bertoletti A, Kennedy P, Gehring AJ ( 2007 ) . Role of the Immune Response in Hepatitis B . Liver Immunology , Springer Nature

Kennedy PTF, Zakaria N, Modawi SB, Papadopoulou AM, Murray-Lyon I, du Bois RM, Andreyev HJN, Devlin J ( 2006 ) . Natural history of hepatic sarcoidosis and its response to treatment . European Journal of Gastroenterology & Hepatology vol. 18 , ( 7 ) 721 - 726 .

Kennedy PTF, Urbani S, Moses RA, Amadei B, Fisicaro P, Lloyd J, Maini MK, Dusheiko G et al. ( 2006 ) . The influence of T cell cross‐reactivity on HCV‐peptide specific human T cell response . Hepatology vol. 43 , ( 3 ) 602 - 611 .

Franzese O, Kennedy PTF, Gehring AJ, Gotto J, Williams R, Maini MK, Bertoletti A ( 2005 ) . Modulation of the CD8+-T-Cell Response by CD4+ CD25+ Regulatory T Cells in Patients with Hepatitis B Virus Infection . Journal of Virology vol. 79 , ( 6 ) 3322 - 3328 .

Zakaria N, Kennedy PTF, Mudawi S, Papadopoulou A, Murray-Lyon I, Dubois R, Devlin J, Andreyev HJN ( 2005 ) . The natural history of hepatic sarcoid . GUT . vol. 54 , A48 - A48 .

Kennedy PTF, O'Grady JG ( 2002 ) . Diseases of the liver: Chronic liver disease . Hospital Pharmacist vol. 9 , ( 5 ) 137 - 144 .

Bateman AC, Thomas KSA, Fine DR, Johnson PA, Johnson CD, Iredale JP ( 2001 ) . 240. FAS-LIGAND PROTECTS ISLET CELLS FROM APOPTOSIS IN CHRONIC PANCREATITIS . Gut vol. 48 , ( suppl 1 )